S&P 500   2,990.83 (-0.16%)
DOW   27,021.95 (-0.01%)
QQQ   192.84 (-0.35%)
AAPL   234.08 (-0.53%)
FB   188.92 (+0.02%)
MSFT   140.09 (-1.05%)
GOOGL   1,247.10 (+0.39%)
AMZN   1,775.65 (+0.47%)
CGC   19.61 (-2.44%)
NVDA   196.51 (+0.07%)
MU   45.89 (-1.21%)
BABA   176.81 (+0.87%)
GE   9.03 (+1.46%)
TSLA   260.99 (+1.20%)
AMD   31.14 (+1.37%)
T   37.89 (-0.05%)
ACB   3.65 (-2.93%)
PRI   124.15 (+0.39%)
NFLX   281.60 (-0.93%)
BAC   30.37 (+2.12%)
GILD   65.68 (+0.58%)
DIS   131.64 (+1.45%)
S&P 500   2,990.83 (-0.16%)
DOW   27,021.95 (-0.01%)
QQQ   192.84 (-0.35%)
AAPL   234.08 (-0.53%)
FB   188.92 (+0.02%)
MSFT   140.09 (-1.05%)
GOOGL   1,247.10 (+0.39%)
AMZN   1,775.65 (+0.47%)
CGC   19.61 (-2.44%)
NVDA   196.51 (+0.07%)
MU   45.89 (-1.21%)
BABA   176.81 (+0.87%)
GE   9.03 (+1.46%)
TSLA   260.99 (+1.20%)
AMD   31.14 (+1.37%)
T   37.89 (-0.05%)
ACB   3.65 (-2.93%)
PRI   124.15 (+0.39%)
NFLX   281.60 (-0.93%)
BAC   30.37 (+2.12%)
GILD   65.68 (+0.58%)
DIS   131.64 (+1.45%)
Log in

Cellectis News Headlines (NASDAQ:CLLS)

$10.24
+0.13 (+1.29 %)
(As of 10/16/2019 12:32 PM ET)
Today's Range
$10.18
Now: $10.24
$10.36
50-Day Range
$9.68
MA: $11.30
$12.76
52-Week Range
$9.50
Now: $10.24
$28.24
Volume17,834 shs
Average Volume128,471 shs
Market Capitalization$434.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74

Headlines

Cellectis (NASDAQ CLLS) News Headlines

Source:
DateHeadline
Cellectis SA (NASDAQ:CLLS) Short Interest UpdateCellectis SA (NASDAQ:CLLS) Short Interest Update
www.americanbankingnews.com - October 12 at 4:19 PM
Genome Editing & Engineering Conference: 2-Day Event (San Diego, CA, United States - February 6-7, 2020) - Yahoo FinanceGenome Editing & Engineering Conference: 2-Day Event (San Diego, CA, United States - February 6-7, 2020) - Yahoo Finance
finance.yahoo.com - October 11 at 6:02 PM
Genome Editing & Engineering Conference: 2-Day Event (San Diego, CA, United States - February 6-7, 2020) - GlobeNewswireGenome Editing & Engineering Conference: 2-Day Event (San Diego, CA, United States - February 6-7, 2020) - GlobeNewswire
www.globenewswire.com - October 11 at 8:01 AM
Cellectis: Monthly Information on Share Capital and Company Voting Rights - StreetInsider.comCellectis: Monthly Information on Share Capital and Company Voting Rights - StreetInsider.com
www.streetinsider.com - October 7 at 6:26 PM
2 Falling Knives Expected to Rebound - Yahoo Finance2 Falling Knives Expected to Rebound - Yahoo Finance
finance.yahoo.com - October 4 at 9:42 PM
Form 6-K Cellectis SA For: Oct 01 - StreetInsider.comForm 6-K Cellectis SA For: Oct 01 - StreetInsider.com
www.streetinsider.com - October 3 at 9:32 PM
$1.40 Million in Sales Expected for Cellectis SA (NASDAQ:CLLS) This Quarter$1.40 Million in Sales Expected for Cellectis SA (NASDAQ:CLLS) This Quarter
www.americanbankingnews.com - October 3 at 10:38 AM
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates - Yahoo FinanceCellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates - Yahoo Finance
finance.yahoo.com - October 3 at 3:22 AM
BRIEF-Cellectis, Lonza Enter cGMP Manufacturing Service Agreement - ReutersBRIEF-Cellectis, Lonza Enter cGMP Manufacturing Service Agreement - Reuters
www.reuters.com - October 1 at 8:48 PM
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis Allogeneic UCART Product Candidates - Business WireCellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates - Business Wire
www.businesswire.com - October 1 at 8:48 PM
 Analysts Expect Cellectis SA (NASDAQ:CLLS) to Post -$0.89 Earnings Per Share Analysts Expect Cellectis SA (NASDAQ:CLLS) to Post -$0.89 Earnings Per Share
www.americanbankingnews.com - October 1 at 9:32 AM
The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger - Yahoo FinanceThe Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger - Yahoo Finance
finance.yahoo.com - September 24 at 3:44 PM
Cellectis SA (NASDAQ:CLLS) Given Average Recommendation of "Hold" by AnalystsCellectis SA (NASDAQ:CLLS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 22 at 2:41 AM
Does Cellectis S.A. (EPA:ALCLS) Have A Particularly Volatile Share Price? - Yahoo Finance UKDoes Cellectis S.A. (EPA:ALCLS) Have A Particularly Volatile Share Price? - Yahoo Finance UK
uk.finance.yahoo.com - September 15 at 1:34 PM
Does Cellectis S.A. (EPA:ALCLS) Have A Particularly Volatile Share Price?Does Cellectis S.A. (EPA:ALCLS) Have A Particularly Volatile Share Price?
finance.yahoo.com - September 15 at 1:34 PM
26 Healthcare Stocks Moving In Thursdays Pre-Market Session - Benzinga26 Healthcare Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - August 15 at 11:41 AM
Xerox passes over several cities, including Phoenix, to bring hundreds of jobs to N.C. - Phoenix Business JournalXerox passes over several cities, including Phoenix, to bring hundreds of jobs to N.C. - Phoenix Business Journal
www.bizjournals.com - August 14 at 9:53 AM
Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 - Yahoo FinanceCellectis Reports Financial Results for Second Quarter and First Six Months 2019 - Yahoo Finance
finance.yahoo.com - August 7 at 9:59 PM
Cellectis EPS misses by $0.29, misses on revenue - Seeking AlphaCellectis EPS misses by $0.29, misses on revenue - Seeking Alpha
seekingalpha.com - August 6 at 10:56 PM
Calyxt to Hold Second Quarter Investor Conference Call on Wednesday, August 7, at 8:30 a.m. EDT – 7:30 a.m. CDT - Yahoo FinanceCalyxt to Hold Second Quarter Investor Conference Call on Wednesday, August 7, at 8:30 a.m. EDT – 7:30 a.m. CDT - Yahoo Finance
finance.yahoo.com - July 22 at 7:07 PM
Imagine Owning Cellectis (EPA:ALCLS) And Wondering If The 45% Share Price Slide Is Justified - Yahoo FinanceImagine Owning Cellectis (EPA:ALCLS) And Wondering If The 45% Share Price Slide Is Justified - Yahoo Finance
finance.yahoo.com - July 17 at 8:55 AM
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way - Business WireCellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way - Business Wire
www.businesswire.com - July 10 at 8:54 AM
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way - Yahoo FinanceCellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way - Yahoo Finance
finance.yahoo.com - July 8 at 6:24 PM
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal WayCellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way
finance.yahoo.com - July 8 at 6:24 PM
Is Solaris Oilfield Infrastructure, Inc. (SOI) A Good Stock To Buy? - Yahoo FinanceIs Solaris Oilfield Infrastructure, Inc. (SOI) A Good Stock To Buy? - Yahoo Finance
finance.yahoo.com - June 27 at 8:59 AM
Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 - Business WireCellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 - Business Wire
www.businesswire.com - June 27 at 8:59 AM
Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy - GlobeNewswireAllogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy - GlobeNewswire
www.globenewswire.com - June 4 at 6:29 PM
Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy - Yahoo FinanceAllogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy - Yahoo Finance
finance.yahoo.com - June 4 at 8:51 AM
Cellectis Reports Financial Results for First Quarter 2019Cellectis Reports Financial Results for First Quarter 2019
finance.yahoo.com - May 29 at 8:47 AM
Outlook On Cellectis Shows Bullish Short-Term Fading In Long Term - Seeking AlphaOutlook On Cellectis Shows Bullish Short-Term Fading In Long Term - Seeking Alpha
seekingalpha.com - May 22 at 8:43 AM
Cellectis beats by $0.40, misses on revenueCellectis beats by $0.40, misses on revenue
seekingalpha.com - May 9 at 8:46 AM
Form 10-Q Allogene Therapeutics, For: Mar 31 - StreetInsider.comForm 10-Q Allogene Therapeutics, For: Mar 31 - StreetInsider.com
www.streetinsider.com - May 8 at 8:47 AM
Cellectis Reports Financial Results for First Quarter 2019 - Yahoo FinanceCellectis Reports Financial Results for First Quarter 2019 - Yahoo Finance
finance.yahoo.com - May 8 at 8:47 AM
Is Fidelity Southern Corporation (LION) A Good Stock To Buy? - Yahoo FinanceIs Fidelity Southern Corporation (LION) A Good Stock To Buy? - Yahoo Finance
finance.yahoo.com - May 6 at 8:48 AM
Is Cellectis SA (CLLS) A Good Stock To Buy? - Yahoo FinanceIs Cellectis SA (CLLS) A Good Stock To Buy? - Yahoo Finance
finance.yahoo.com - May 6 at 8:48 AM
Key events next week - healthcare (Part 1) - Seeking AlphaKey events next week - healthcare (Part 1) - Seeking Alpha
seekingalpha.com - April 26 at 6:39 PM
Precision Biosciences, Recent IPO: Unique ARCUS Gene Editing And Allogeneic CAR-T PlatformPrecision Biosciences, Recent IPO: Unique ARCUS Gene Editing And Allogeneic CAR-T Platform
seekingalpha.com - April 22 at 8:35 AM
Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting - Business WireCellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting - Business Wire
www.businesswire.com - April 18 at 7:09 PM
Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual MeetingCellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting
finance.yahoo.com - April 17 at 7:04 PM
Allogene Therapeutics (ALLO) Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 in MM - StreetInsider.comAllogene Therapeutics (ALLO) Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 in MM - StreetInsider.com
www.streetinsider.com - April 16 at 7:21 PM
Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma - GlobeNewswireAllogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma - GlobeNewswire
globenewswire.com - April 15 at 10:18 AM
Cellectis: Monthly Information on Share Capital and Company Voting Rights - Business WireCellectis: Monthly Information on Share Capital and Company Voting Rights - Business Wire
www.businesswire.com - April 5 at 7:21 PM
Cellectis on go with early-stage study of CAR-T for multiple myeloma - Seeking AlphaCellectis on go with early-stage study of CAR-T for multiple myeloma - Seeking Alpha
seekingalpha.com - April 2 at 8:58 PM
Cellectis (CLLS) Announces FDA Clears IND for UCARTCS1 - StreetInsider.comCellectis (CLLS) Announces FDA Clears IND for UCARTCS1 - StreetInsider.com
www.streetinsider.com - April 2 at 8:58 PM
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma PatientsFDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
finance.yahoo.com - April 2 at 8:58 PM
Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART PortfolioCellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio
finance.yahoo.com - March 7 at 6:40 PM
Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological ChemistryCellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry
finance.yahoo.com - February 25 at 6:44 PM
Cellectis Appoints William Monteith as Senior Vice President U.S. ManufacturingCellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing
finance.yahoo.com - December 10 at 5:15 PM
Cellectis misses by $0.01, misses on revenueCellectis misses by $0.01, misses on revenue
seekingalpha.com - November 14 at 8:32 AM
Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018
finance.yahoo.com - November 13 at 4:58 PM
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Conference Calls

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel